Regulus Therapeutics Inc. (NASDAQ:RGLS) went down by -10.33% from its latest closing price compared to the recent 1-year high of $2.32. The company’s stock price has collected -3.41% of loss in the last five trading sessions. Press Release reported on 09/09/21 that Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Is It Worth Investing in Regulus Therapeutics Inc. (NASDAQ :RGLS) Right Now?
Plus, the 36-month beta value for RGLS is at 2.20. Opinions of the stock are interesting as 2 analysts out of 4 who provided ratings for Regulus Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $1.38, which is $0.42 above the current price. RGLS currently public float of 64.71M and currently shorts hold a 7.66% ratio of that float. Today, the average trading volume of RGLS was 1.85M shares.
RGLS’s Market Performance
RGLS stocks went down by -3.41% for the week, with a monthly jump of 8.68% and a quarterly performance of -23.95%, while its annual performance rate touched 44.50%. The volatility ratio for the week stands at 5.72% while the volatility levels for the past 30 days are set at 7.19% for Regulus Therapeutics Inc.. The simple moving average for the period of the last 20 days is 2.41% for RGLS stocks with a simple moving average of -32.95% for the last 200 days.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with B. Riley FBR Inc. repeating the rating for RGLS by listing it as a “Neutral.” The predicted price for RGLS in the upcoming period, according to B. Riley FBR Inc. is $1 based on the research report published on March 28th of the previous year 2018.
Leerink Partners, on the other hand, stated in their research note that they expect to see RGLS reach a price target of $2. The rating they have provided for RGLS stocks is “Outperform” according to the report published on January 05th, 2018.
Chardan Capital Markets gave a rating of “Buy” to RGLS, setting the target price at $2.50 in the report published on June 13th of the previous year.
RGLS Trading at 2.34% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.62% of loss for the given period.
Volatility was left at 7.19%, however, over the last 30 days, the volatility rate increased by 5.72%, as shares surge +12.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.01% lower at present.
During the last 5 trading sessions, RGLS fell by -3.41%, which changed the moving average for the period of 200-days by +25.08% in comparison to the 20-day moving average, which settled at $0.7375. In addition, Regulus Therapeutics Inc. saw -44.36% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at RGLS starting from Hagan Joseph P, who sale 4,186 shares at the price of $0.89 back on May 17. After this action, Hagan Joseph P now owns 316,292 shares of Regulus Therapeutics Inc., valued at $3,726 using the latest closing price.
Aker Christopher Ray, the Sr. VP & General Counsel of Regulus Therapeutics Inc., sale 860 shares at $0.89 during a trade that took place back on May 17, which means that Aker Christopher Ray is holding 41,754 shares at $765 based on the most recent closing price.
Stock Fundamentals for RGLS
Current profitability levels for the company are sitting at:
- -141.47 for the present operating margin
The net margin for Regulus Therapeutics Inc. stands at -157.21. The total capital return value is set at -42.58, while invested capital returns managed to touch -68.25. Equity return is now at value -61.00, with -38.60 for asset returns.
Based on Regulus Therapeutics Inc. (RGLS), the company’s capital structure generated 19.69 points at debt to equity in total, while total debt to capital is 16.45.
When we switch over and look at the enterprise to sales, we see a ratio of 2.12, with the company’s debt to enterprise value settled at 0.24. The receivables turnover for the company is 12.17 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.